RxDoctor Payments DataLook up a doctor →

Marc Feinberg, MD

Neurology · Boca Raton, FLNPI 1255422127

Payments from drug & device makers

$3,169,625in general payments, 2019–2025

Across 875 payments — averaging $3622.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$723K
  • Janssen Research & Development, LLC$613K
  • E.r. Squibb & Sons, L.L.C.$412K
  • Novartis$333K
  • Argenx US, Inc.$254K
  • UCB SA$208K
  • plus $628K from 54 others
$145,951in research payments, 2019–2025

Across 25 payments — averaging $5838.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$107K
  • Acadia Pharmaceuticals Inc$38K
  • Merck Healthcare Kgaa$860
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$632

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly30$722,598
Janssen Research & Development, LLC45$612,682
E.r. Squibb & Sons, L.L.C.6$411,595
Novartis59$332,606
Argenx US, Inc.50$254,055
UCB SA3$207,987
H. Lundbeck A S49$159,653
Sanofi57$148,395
Genentech, Inc.5$53,678
AstraZeneca(2 entities)41$53,088
Otsuka Pharmaceutical Development & Commercialization, Inc.7$40,031
AbbVie(2 entities)99$38,324
Avanir Pharmaceuticals, Inc.11$27,395
Takeda Pharmaceuticals U.S.A., Inc.15$21,607
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$14,150
Acadia Pharmaceuticals Inc61$11,680
Ares Trading SA3$11,309
Regeneron4$11,270
Biogen9$8,126
F. Hoffmann-la Roche AG1$6,000
Sanofi US Services Inc.1$5,000
Johnson & Johnson(2 entities)23$4,756
Hoffmann-la Roche Limited2$3,500
Catalyst Pharmaceuticals, Inc.3$1,836
Eisai Inc.2$1,670
Biotronik Inc.7$940
Genentech USA, Inc.29$667
Amgen(2 entities)31$619
EMD Serono, Inc.27$488
Lundbeck LLC20$480
Lilly USA, LLC20$346
UCB, Inc.14$326
Teva Pharmaceuticals USA, Inc.16$284
Bristol Myers Squibb13$237
Pfizer10$224
CSL Behring8$207
MDD US Operations, LLC10$202
Merz Pharmaceuticals, LLC7$156
Neurocrine Biosciences, Inc.6$133
Supernus Pharmaceuticals, Inc.5$106
C2n Diagnostics, LLC5$102
Acorda Therapeutics, Inc5$101
Amneal Pharmaceuticals LLC5$76
Avion Pharmaceuticals4$67
Vanda Pharmaceuticals Inc.3$62
Arbor Pharmaceuticals, Inc.3$59
Grifols USA, LLC3$56
Biohaven Pharmaceuticals, Inc.3$56
Tanabe Pharma America, Inc.3$53
Insightec,inc2$50
Merz North America, Inc.2$50
Mallinckrodt Hospital Products Inc.2$48
Harmony Biosciences LLC1$40
Kyowa Kirin, Inc.2$39
Bausch Health US, LLC2$36
Greenwich Biosciences, Inc.2$35
Vertical Pharmaceuticals, LLC1$33
Medtronic(2 entities)2$32
Biohaven Pharmaceutical Holding Company Ltd.2$29
Revance Therapeutics, Inc.1$28

How this compares

$3,169,625 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$443,571
Medicare patients
1,397
Services billed
4,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Boca Raton

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →